Sonoma Biotherapeutics is a privately held company developing regulatory T cell (Treg) therapies for autoimmune and degenerative diseases.
Sonoma Biotherapeutics is inventing the future of living therapies for autoimmune disease — safe, effective treatments as unique as each individual patient.
Sonoma Biotherapeutics was founded in 2019 by Jeffrey Bluestone, Fred Ramsdell, Alexander Rudensky and Qizhi Tang. The company is headquartered in South San Francisco, California, with an office in Seattle, Washington.
Sonoma brings together next-generation research, development and manufacturing capabilities in cell therapy and genetic engineering with an accomplished team of executives, scientists, board members and investors with extensive experience in the fields of cell therapy and drug discovery.
Sonoma’s mission is to create a best-in-class regulatory T cell therapy that delivers long-lasting, highly efficacious treatments leading to cures across a spectrum of autoimmune and degenerative diseases.
Sonoma, by using next generation genome editing and target-specific cell therapy, is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities.
Sonoma Biotherapeutics has raised $40M in a Series A round of funding on Feb 06, 2020. The investment was backed by Lyell Immunopharma, ARCH Venture Partners, Milky Way Ventures and 8VC.